Chief Operating Officer | Empowered teams + focused processes + enabling tools fuel remarkable growth

Date of management change: February 24, 2025 

What Happened?

 

About the Company

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company`s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.

 

About the Person

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Palmer Adam, Beckman Paul, Callas Jon, Park Ernie, Khan Rita, Arora Vishal, Davis Sam, Kitograd Brian, Wikstrom Bill, Sitaru Sabina, Kahn Jack

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.